Cargando…

Immunomagnetic Reduction Detects Plasma Aβ(1–42) Levels as a Potential Dominant Indicator Predicting Cognitive Decline

Although the concentrations of Alzheimer’s disease (AD) biomarkers Aβ(1–40), Aβ(1–42) and tau protein are very low in human plasma, ultrasensitive assays such as immunomagnetic reduction (IMR) are able to precisely quantify them. Review articles have described the detailed working mechanism of IMR a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Shieh-Yueh, Liu, Huei-Chun, Chen, Wen-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606390/ https://www.ncbi.nlm.nih.gov/pubmed/33090326 http://dx.doi.org/10.1007/s40120-020-00215-2

Ejemplares similares

Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology
por: Liu, Huei-Chun, et al.
Publicado: (2020)

Long-Term Storage Effects on Stability of Aβ(1–40), Aβ(1–42), and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays
por: Chiu, Ming-Jang, et al.
Publicado: (2019)

Investigation of the Number of Tests Required for Assaying Plasma Biomarkers Associated with Alzheimer’s Disease Using Immunomagnetic Reduction
por: Liu, Huei-Chun, et al.
Publicado: (2021)

Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer’s Disease
por: Yang, Shieh-Yueh, et al.
Publicado: (2017)

Development of a 36-Channel Instrument for Assaying Biomarkers of Ultralow Concentrations Utilizing Immunomagnetic Reduction
por: Chen, Hsin-Hsien, et al.
Publicado: (2022)

Stability of Plasma Amyloid-β 1–40, Amyloid-β 1–42, and Total Tau Protein over Repeated Freeze/Thaw Cycles
por: Liu, Huei-Chun, et al.
Publicado: (2020)

Use of immunomagnetic reduction for C-reactive protein assay in clinical samples
por: Chang, Chien-Hsi, et al.
Publicado: (2012)

Plasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment
por: Chen, Ting-Bin, et al.
Publicado: (2019)

Assessment of Plasma Amyloid-β(42/40) and Cognitive Decline Among Community-Dwelling Older Adults
por: Giudici, Kelly Virecoulon, et al.
Publicado: (2020)

Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects
por: Lue, Lih-Fen, et al.
Publicado: (2019)

Applications of Immunomagnetic Reduction Technology as a Biosensor in Therapeutic Evaluation of Chinese Herbal Medicine in Tauopathy Alleviation of an AD Drosophila Model
por: Su, Ming-Tsan, et al.
Publicado: (2022)

Is postoperative cognitive decline after cardiac surgery associated with plasma beta amyloid 1–42 levels?
por: Požgain, Zrinka, et al.
Publicado: (2022)

Corrigendum: Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects
por: Lue, Lih-Fen, et al.
Publicado: (2019)

Plasma α-synuclein predicts cognitive decline in Parkinson’s disease
por: Lin, Chin-Hsien, et al.
Publicado: (2017)

Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
por: Lue, Lih-Fen, et al.
Publicado: (2017)

A Novel Detection Platform for Shrimp White Spot Syndrome Virus Using an ICP11-Dependent Immunomagnetic Reduction (IMR) Assay
por: Liu, Bing-Hsien, et al.
Publicado: (2015)

Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology
por: Lue, Lih-Fen, et al.
Publicado: (2019)

Validation of Assaying Carcinoembryonic Antigen in Human Serum by Using Immunomagnetic Reduction
por: Wei, Po-Li, et al.
Publicado: (2018)

Synergistic Association between Plasma Aβ(1–42) and p-tau in Alzheimer’s Disease but Not in Parkinson’s Disease or Frontotemporal Dementia
por: Chiu, Ming-Jang, et al.
Publicado: (2021)

Plasma p‐tau181/Aβ(1‐42) ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ(1‐42) and future cognitive decline
por: Fowler, Christopher J., et al.
Publicado: (2022)

The Association of Plasma Amyloid-β and Cognitive Decline in Cognitively Unimpaired Population
por: Wang, Jin, et al.
Publicado: (2022)

Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline
por: Pascual-Lucas, María, et al.
Publicado: (2023)

Quantitative analysis of total β-subunit of human chorionic gonadotropin concentration in urine by immunomagnetic reduction to assist in the diagnosis of ectopic pregnancy
por: Chen, Chen-Yu, et al.
Publicado: (2015)

APOE-ε4 modulates the association among plasma Aβ(42)/Aβ(40), vascular diseases, neurodegeneration and cognitive decline in non-demented elderly adults
por: Shi, Dai, et al.
Publicado: (2022)

CSF Aβ(1–42) level is associated with cognitive decline in early Parkinson’s disease with rapid eye movement sleep behavior disorder
por: Ba, Maowen, et al.
Publicado: (2018)

Aβ1-42-containing platelet-derived extracellular vesicle is associated with cognitive decline in Parkinson’s disease
por: Wang, Ziyu, et al.
Publicado: (2023)

Non-linear Relationship Between Plasma Amyloid-β 40 Level and Cognitive Decline in a Cognitively Normal Population
por: Gao, Fan, et al.
Publicado: (2020)

Evidence of plasma biomarkers indicating high risk of dementia in cognitively normal subjects
por: Pai, Ming-Chyi, et al.
Publicado: (2022)

Effective Isolation for Lung Carcinoma Cells Based on Immunomagnetic Separation in a Microfluidic Channel
por: Vu-Dinh, Hien, et al.
Publicado: (2021)

Immunomagnetic nanoparticle-based assays for detection of biomarkers
por: Park, Hoyoung, et al.
Publicado: (2013)

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
por: Stockmann, Julia, et al.
Publicado: (2020)

Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease
por: Chen, Nai-Ching, et al.
Publicado: (2020)

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
por: Fandos, Noelia, et al.
Publicado: (2017)

Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ(42)
por: An, Seong Soo A., et al.
Publicado: (2017)

CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders
por: Mattsson, N, et al.
Publicado: (2013)

Plasma Aβ(42):Aβ(40) ratio as a biomarker for cognitive impairment in haemodialysis patients: a multicentre study
por: Chen, Xujiao, et al.
Publicado: (2023)

Aging and APOE‐ε4 are determinative factors of plasma Aβ42 levels
por: Nakamura, Takumi, et al.
Publicado: (2018)

Association Between Plasma Amyloid-β and Neuropsychological Performance in Patients With Cognitive Decline
por: Yun, Gyihyaon, et al.
Publicado: (2021)

Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
por: Stockmann, Julia, et al.
Publicado: (2021)

Early Indications of Future Cognitive Decline: Stable versus Declining Controls
por: Rizk-Jackson, Angela, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dmdlo71ju6islgib0qksqto607